The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed the day trading at $160.25 down -5.38% from the previous closing price of $169.37. In other words, the price has decreased by -$5.38 from its previous closing price. On the day, 2.34 million shares were traded. JAZZ stock price reached its highest trading level at $171.025 during the session, while it also had its lowest trading level at $156.95.
Ratios:
For a better understanding of JAZZ, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.29. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.11.
On July 15, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $152.
UBS Upgraded its Neutral to Buy on March 07, 2025, whereas the target price for the stock was revised from $145 to $179.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’25 when Henderson Mary Elizabeth sold 2,238 shares for $169.51 per share. The transaction valued at 379,366 led to the insider holds 19,508 shares of the business.
MARY ELIZABETH HENDERSON bought 2,238 shares of JAZZ for $379,365 on Dec 09 ’25. On Dec 05 ’25, another insider, Carr Patricia, who serves as the SVP, Chief Accounting Officer of the company, sold 4,660 shares for $171.20 each. As a result, the insider received 797,783 and left with 7,012 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 9737610240 and an Enterprise Value of 13120499712. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.34 while its Price-to-Book (P/B) ratio in mrq is 2.46. Its current Enterprise Value per Revenue stands at 3.156 whereas that against EBITDA is 8.159.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.26, which has changed by 0.39502513 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $182.99, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is -0.52%, while the 200-Day Moving Average is calculated to be 24.68%.
Shares Statistics:
Over the past 3-months, JAZZ traded about 1.07M shares per day on average, while over the past 10 days, JAZZ traded about 906330 shares per day. A total of 60.74M shares are outstanding, with a floating share count of 57.98M. Insiders hold about 4.59% of the company’s shares, while institutions hold 100.46% stake in the company. Shares short for JAZZ as of 1765756800 were 5042462 with a Short Ratio of 4.73, compared to 1763078400 on 4839654. Therefore, it implies a Short% of Shares Outstanding of 5042462 and a Short% of Float of 9.59.
Earnings Estimates
. The current market rating for Jazz Pharmaceuticals plc (JAZZ) reflects the collective analysis of 14.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $3.97, with high estimates of $5.96 and low estimates of $2.59.
Analysts are recommending an EPS of between $8.82 and $7.73 for the fiscal current year, implying an average EPS of $8.09. EPS for the following year is $22.04, with 14.0 analysts recommending between $26.92 and $19.42.
Revenue Estimates
14 analysts predict $1.16B in revenue. The current quarter. It ranges from a high estimate of $1.22B to a low estimate of $1.11B. As of . The current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.09BFor the next quarter, 14 analysts are estimating revenue of $977.3M. There is a high estimate of $1.1B for the next quarter, whereas the lowest estimate is $899M.
A total of 16 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.29B, while the lowest revenue estimate was $4.18B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $4.07BBased on 16 analysts’ estimates, the company’s revenue will be $4.5B in the next fiscal year. The high estimate is $4.79B and the low estimate is $4.12B.
